Please ensure Javascript is enabled for purposes of website accessibility

Why Fortress Biotech Stock Is Sinking Today

By Keith Speights - Jun 14, 2021 at 12:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA refused to approve IV tramadol for the second time.

What happened

Shares of Fortress Biotech (FBIO -8.26%) were sinking 12.9% as of 12:20 p.m. EDT on Monday. The decline came after the company announced that it received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its regulatory submission seeking approval of intravenous tramadol in treating acute pain.

So what

A thumbs-down from the FDA is never good news for a small biotech stock. It's especially concerning when the agency turns down a drug twice.

A rubber stamp with red ink that says "Not FDA Approved."

Image source: Getty Images.

The first time the FDA refused to approve IV tramadol, the reason given was the drug wasn't safe for the intended patient group. It was a similar story this time around. 

Fortress said the FDA thought that there wasn't enough information in the New Drug Application (NDA) supporting the safety of IV tramadol in combination with other pain relievers for the intended patient population. The agency also questioned the efficacy of the drug in combination with other analgesics as well as its clinical benefit as a monotherapy.

Now what

Fortress seems to think that the third time could be the charm. The company stated that it "intends to continue to pursue regulatory approval for IV tramadol."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fortress Biotech, Inc. Stock Quote
Fortress Biotech, Inc.
$1.11 (-8.26%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.